Furopyridine compounds for the treatment of hepatitis c

A compound of formula I

• wherein
• R0 and R1 are independently hydrogen or methyl;
• R2 is optionally substituted aryl with 0-2 halo or methoxy;
• R3, R4, R5 and R8 are independently hydrogen or halo;
• R6 is hydrogen, halo, optionally substituted C1-C6 alkyl or optionally substituted C1-C6 alkoxy;
• R7 is COOR101 or CON(R102)(R103);
• R101 is hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C8 cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy;
• R102 and R103 are each independently hydrogen, —(CR10R11)R12, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, with 0-3 substituents selected from halo, OH, OR104, NH2, NR105R106, COOR104, CONR105R106, S(O)2R104, S(O)2NR105R106, NR104CONR105R106, OR104CONR105R106, C(═NR107)NR105R106, NR108C(═NR107)NR105R106, haloalkoxy;
• or
• R102 and R103 can form a ring by joining two atoms, one from each of R102 and R103;
• or
• R102 and R103 can form bicyclic or tricyclic rings by joining multiple atoms from each of R102 and R103;
• R104 is hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C8 cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy;
• R105 and R106 are each independently hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C8 cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy;
• or
• R105 and R106 can form a ring by joining two atoms, one from each of R105 and R106;
• R107 and R108 are each independently hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C8 cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy;
• or
• R107 and R108 can form a ring by joining two atoms, one from each of R107 and R108;
• R10 and R11 are independently hydrogen or C1-C6 alkyl;
• R12 is substituted C1-C6 alkynyl, C3-C8 cycloalkyl, —COO C1-C6 alkyl, phenyl or CF2CF3;
• R9 is R201, NHR201 or NR201R202;
• R201 and R202 are each independently hydrogen, halo, alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl with 1-4 substituents selected from halo, hydroxyl, alkoxy, haloalkoxy and phenyl;
• and/or a pharmaceutically acceptable salt or stereoisomer thereof.